Ignite Creation Date:
2024-05-06 @ 6:06 PM
Last Modification Date:
2024-10-26 @ 2:41 PM
Study NCT ID:
NCT05549505
Status:
COMPLETED
Last Update Posted:
2024-05-07
First Post:
2022-09-07
Brief Title:
A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery
Sponsor:
Arvinas Inc
Organization:
Arvinas Inc
Study Overview
Official Title:
An Open-label Randomized Non-comparative Phase 2 Study of ARV-471 or Anastrozole in Post-menopausal Women With ERHER2- Breast Cancer in the Neoadjuvant Setting
Status:
COMPLETED
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This trial is a Phase 2 neoadjuvant study evaluating ARV-471 or anastrozole in post-menopausal women with ERHER2- localized breast cancer
Detailed Description:
This is a Phase 2 open-label randomized non-comparative proof of concept study of ARV-471 or anastrozole in participants with ERHER2- breast cancer amenable to definitive surgical resection The main goal of this study is to evaluate the biological activity of ARV-471 and anastrozole respectively
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| C4891025 | OTHER | Pfizer | None |